Novasep Appoints Nadege Laborde as President of its Industrial Biotech Business Unit
News Nov 22, 2013
Novasep has announced the appointment of Nadege Laborde as the new president of its Industrial Biotech business unit. This internal promotion strengthens the business unit and is a key addition to the Executive Committee (COMEX).
The nomination recognizes and rewards all of the commitment and skill that Nadege has demonstrated within the business.
Nadege joined Novasep in 2000 after qualifying as an engineer from Ecole Centrale, Paris. She started at Novasep as a project manager and expanded her responsibilities as an engineering manager in the US and Asia.
Since 2009 she has headed the system engineering and construction department and driven her multicultural team in France and China towards achieving both operational excellence and customer satisfaction.
Nadege has implemented strategic cost optimizations and innovated across both industrial process design and the worldwide supply chain enabling an average double-digit growth of industrial biotech unit sales over the last four years.
Nadege Laborde will expand Novasep’s market reach into new geographical territories.
“I am convinced Novasep as a group has a strong growth potential. I’m eager to support our continued development in all areas,” says Nadege.
“I’m very pleased to welcome Nadege Laborde as the new president of the industrial biotech business unit. Her nomination is another milestone in Novasep’s senior management recruitment program,” says Michel Spagnol, CEO.
Spagnol continued, “With a passion for industrial processes, Nadege has delivered consistent customer results over the last decade. She has been instrumental in maintaining and developing our world leadership across a broad range of markets and applications.”
Novasep is on track for continued growth and expansion and poised to continue delivering value-added solutions to global customers.
Michel says: “With the scientific expertise of its teams, the Novasep industrial biotech business unit has a proven ability to innovate, resulting in a uniquely diversified offer and a wide range of client references in traditional markets. I firmly believe our business unit has the capacity to accelerate its growth and to generate increasing sales and profitability.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019